NDA 204325 · Neos Theraps INC
Adzenys Er
Amphetamine · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Sep 15, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
392
60 Phase 3, 36 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 15, 2017 Original approval · Type 3 - New Dosage Form LabelMedication GuidePediatric Medical Review
1 products under this application
- ADZENYS ER · AMPHETAMINE EQ 1.25MG BASE/ML · SUSPENSION, EXTENDED RELEASE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Amphetamine" as an intervention, any sponsor and status, largest first.
- A Toolbox Approach to Obesity Treatment in Primary CarePivotal-lookingCompleted
Denver Health and Hospital AuthorityAcademic, hospital or other
NCT01922934 · 4,730 participants · Start Jan 2014 · Primary completion Aug 2016
Drug: Obesity pharmacotherapy · For: Obesity
Sites: Denver, Colorado
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01435759 · 1,197 participants · Start May 31, 2011 · Primary completion Jan 17, 2014
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg and 3 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Chino, California · 82 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436162 · 1,105 participants · Start Oct 19, 2011 · Primary completion Dec 10, 2013
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo · For: Major Depressive Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Costa Mesa, California · 101 sites in all
- Long-term Effectiveness of the Antiobesity Medication PhenterminePivotal-lookingCompleted
Wake Forest University Health SciencesAcademic, hospital or other
NCT05176626 · 870 participants · Start Jun 30, 2022 · Primary completion Sep 30, 2026
Drug: Phentermine Hydrochloride 8 MG · For: Obesity; Obesity; Drug; Lifestyle, Healthy
Sites: Los Angeles, California; Saint Louis Park, Minnesota; Winston-Salem, North Carolina · 4 sites in all
- The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)Pivotal-lookingRecruiting
International Peace Maternity and Child Health HospitalAcademic, hospital or other
NCT06006091 · 858 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2026
Drug: Letrozole · For: Letrozole; Infertility, Female
Sites: Shanghai, China
- A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00563368 · 756 participants · Start Dec 2007 · Primary completion Sep 2008
Drug: VI-0521; VI-0521 and 5 more · For: Obesity
Sites: Durham, North Carolina; Philadelphia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
Faraone SV · Neurosci Biobehav Rev 2018 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.
Murrie B, Lappin J, Large M, et al. · Schizophr Bull 2020 · Meta-Analysis, Systematic Review
- Substance use and spine density: a systematic review and meta-analysis of preclinical studies.
Oliva HNP, Prudente TP, Nunes EJ, et al. · Mol Psychiatry 2024 · Systematic Review, Meta-Analysis
- The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F, Hutton B, Núñez-Beltrán A, et al. · PLoS One 2017 · Systematic Review, Network Meta-Analysis
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Tardelli VS, Bisaga A, Arcadepani FB, et al. · Psychopharmacology (Berl) 2020 · Meta-Analysis, Systematic Review
- Methamphetamine use and illicit opioid use during buprenorphine treatment.
Kratina-Hathaway Z, Radick AC, Leroux BG, et al. · J Subst Use Addict Treat 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Neos Theraps INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.